Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $4.32 per share versus the Zacks Consensus Estimate of a loss of $3.8. This compares to a loss of $3 per share a year ago.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Brendan Twohig Strong - Corporate Participant SVP of Investor Relations & Corporate Communications - Corporate Participant Lori A. Macomber - EVP, CFO & Treasurer Reshma Rangwala - Executive VP, Chief Medical Officer & Head of Research Richard A.

– New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million; Updates U.S. XPOVIO Net Product Revenue Guidance to $110 Million to $120 Million – – The Company is Exploring Financing Transactions and Strategic Alternatives to Extend its Cash Runway and Maximize Value – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass.

-- Conference Call Scheduled for Monday, August 11, 2025, at 8:00 a.m. ET -- NEWTON, Mass.

NEWTON, Mass. , Aug. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 333 restricted stock units (RSUs) to one newly-hired employee.

Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEWTON, Mass. , July 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 666 restricted stock units (RSUs) to two newly-hired employees.

NEWTON, Mass. , June 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 3:10 p.m.

NEWTON, Mass. , June 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 566 restricted stock units (RSUs) to two newly-hired employees.

Karyopharm Therapeutics (KPTI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 521.6% in Karyopharm Therapeutics (KPTI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

NEWTON, Mass. , May 19, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2025 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 21 at 10:00 a.m.

NEWTON, Mass. , May 14, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy.

Karyopharm Therapeutics Inc. KPTI reported mixed financial results for the first quarter on Monday.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Brendan Strong - Senior Vice President, Investor Relations & Corporate Communications Richard Paulson - President & Chief Executive Officer Reshma Rangwala - Chief Medical Officer & Head, Research Sohanya Cheng - Chief Commercial Officer & Head, Business Development Lori Macomber - Chief Financial Officer & Treasurer Conference Call Participants Colleen Kusy - Baird Ted Tenthoff - Piper Sandler Peter Lawson - Barclays Albert Agustinus - Leerink Partners Operator Good afternoon. My name is Chloe, and I will be your conference operator today.

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.77 per share versus the Zacks Consensus Estimate of a loss of $4.21. This compares to loss of $4.80 per share a year ago.